Avantor, Inc.
Long

$AVTR | Direction: Long | Key Reason | (June 20, 2025)

49
AVTR | Direction: Long | Key Reason: Fundamentals & Technical | (June 20, 2025)

1️⃣ Insight Summary
AVTR is showing strong fundamentals, with ~$7 billion in revenue and ~$700 million net income. As a healthcare and medical-tech distributor since 1904, it has survived major crises and now sees accelerated flow-in from institutional and retail buyers—making now an ideal pull-back entry before heading higher.

2️⃣ Trade Parameters
Bias: Long
Entry: Around $9.00–$9.35 (current price)
Stop Loss: Below $8.50
Take Profit 1: $15.95
Take Profit 2: $19.90
Take Profit 3: $23.00
Max Target: Holding long could stretch to $34.54 (prior major swing), depending on macro support

3️⃣ Key Notes
✅ Massive scale & history – Founded in 1904, AVTR has weathered wars and crises with ~$7 billion revenue and ~$700 million net income.
✅ Sector & services – Operates in healthcare distribution, advanced-tech, biopharma, education, and government sectors, giving broad exposure and stability.
✅ Capital flows – Capital inflow is strong; both retail (call volume) and institutions are showing buying interest.
✅ Technical outlook – With aggressive money flow and a recent consolidation near $9.35, a breakout could propel prices toward $15–23.
✅ Macro driver – Strength in the S&P 500 and healthcare sector momentum may support the run-up to the $34.54 zone.

4️⃣ Follow‑up Note
I’ll monitor market correlation with the S&P 500 and sector rotation. If flows continue and AVTR breaks out decisively above $10–11, holding through $23 and possibly $34.54 becomes more likely.

Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! This is the best way to keep it relevant, support us, keep the content here free and allow the idea to reach as many people as possible.

Disclaimer: This is not financial advice. Always conduct your own research. This content may include enhancements made using AI.

Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.